Refeyn, a mass photometry technology company, has announced it will open its new US Headquarters and Customer Interaction Centre in conjunction with the third annual Mass Photometry Summit 2024.
After the summit on May 2022, Refeyn will officially open its new 10,000 sqft HQ in the heart of Waltham's Biotech Hub in Greater Boston, MA, on May 23.
Serving customers in North America
With its new US Customer Interaction Center sited within one of the world’s largest biotech hubs, Refeyn can directly support the many world-leading bioscience companies and university-based researchers in the area and beyond.
Waltham’s proximity to Boston Logan International Airport also makes the new HQ readily accessible to its customers from across the continent.
Mass Photometry Summit 2024
Building on previous events, Refyn's 2024 summit offers scientists the opportunity to engage in scientific discussions to learn more about mass photometry and its applications. From user talks and poster presentations, attendees can see how this novel light-based analytical technology is being used in a range of scientific fields.
There will also be opportunity to hear about Refeyn’s very latest products through interactive demonstrations — with the launch of new instruments, accessories and cGMP software since last year’s summit, mass photometry technologies are now a solution for many more applications. The event is free to attend and requires advance registration.
The HQ's facilities
Refeyn’s new Boston area HQ offers many new facilities — in addition to offices and meeting and training rooms, there is laboratory space supported by state-of-the-art lab tools. The laboratory space includes a BSL-2 lab, service centre, R&D centre and applications lab.
In Waltham, Refeyn is also looking to expand its workforce and will be recruiting additional employees for the new facility, which will accommodate over 40 personnel.
Gerry Mackay, CEO at Refeyn, commented: “This opening is a testament to Refeyn’s rapid growth with the ever-increasing success of mass photometry as it is deployed in life science laboratories around the world – for biophysical characterisation and to analyse next-generation biotherapeutics, to support scientific discovery and therapeutics R&D and manufacture. We are excited to invest in Waltham and join the buzz in New England’s fast-emerging biotech hub.”
